Barclays chief: the life lessons I have discovered during cancer treatment
CS Venkatakrishnan gives his personal account of leading the bank while undergoing care for non-Hodgkin lymphoma (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - February 4, 2023 Category: Pharmaceuticals Source Type: news

Heart Failure Risk Lingers Long After Chemotherapy, Regardless of Dose
(MedPage Today) -- Anthracycline users with breast cancer or lymphoma had an upfront risk of congestive heart failure (CHF) that persisted during long-term follow-up in a population-based case-control study. The cumulative incidence of new-onset... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - February 3, 2023 Category: Cardiology Source Type: news

PET/MRI an effective alternative to PET/CT for lymphoma management
With the benefit of reduced exposure to radiation, PET/MRI could become a practica...Read more on AuntMinnie.comRelated Reading: Brain PET/MRI scans reveal visual snow syndrome Pylarify PET/MRI shows value in selecting patients for focal ablative therapy PET/MRI shows promise for imaging infection, inflammation How low can FDG dose go on PET/MRI? For staging endometrial cancer: PET/MRI or PET/CT? (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - February 3, 2023 Category: Radiology Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results for 2022 despite decline in demand for COVID-19 products
Basel, 2 February 2023Group sales grow by 2%1 at constant exchange rates (CER) and 1% in Swiss francs, despite lower COVID-19-related sales in both divisionsPharmaceuticals Division salesincrease by 2%; continued strong growth of newer medicines more than compensating for the impact of biosimilars and lower sales of Actemra/RoActemra (severe COVID-19)Diagnostics Division salesgrow by 3%; ongoing strong momentum in base business (+7%) more than compensating for the continuing decline in the demand for COVID-19 tests in the second half of the yearHighlightsin the fourth quarter of 2022 (incl. January 2023):US approvals ofLun...
Source: Roche Media News - February 2, 2023 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results for 2022 despite decline in demand for COVID-19 products
Group sales grow by 2%1 at constant exchange rates (CER) and 1% in Swiss francs, despite lower COVID-19-related sales in both divisionsPharmaceuticals Division salesincrease by 2%; continued strong growth of newer medicines more than compensating for the impact of biosimilars and lower sales of Actemra/RoActemra (severe COVID-19)Diagnostics Division salesgrow by 3%; ongoing strong momentum in base business (+7%) more than compensating for the continuing decline in the demand for COVID-19 tests in the second half of the yearHighlightsin the fourth quarter of 2022 (incl. January 2023):US approvals ofLunsumio (follicular lymp...
Source: Roche Investor Update - February 2, 2023 Category: Pharmaceuticals Source Type: news

Episode 2: Mantle Cell Lymphoma International Prognostic Index and MRD Episode 2: Mantle Cell Lymphoma International Prognostic Index and MRD
Drs Peter Martin and Eva Hoster discuss minimal residual disease, the Mantle Cell Lymphoma International Prognostic Index, and newer variable additions and their role in understanding recent findings.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 31, 2023 Category: Consumer Health News Tags: Hematology-Oncology InDiscussion Source Type: news

Chemo in Afternoon Works Better Than in Morning, but Only in Women Chemo in Afternoon Works Better Than in Morning, but Only in Women
For women with diffuse large B-cell lymphoma undergoing chemotherapy, survival was better with less toxicity when the drugs were administered in the afternoon than in the morning.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 31, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Episode 1: Autologous Stem Cell Transplant for Mantle Cell Lymphoma Episode 1: Autologous Stem Cell Transplant for Mantle Cell Lymphoma
Drs Peter Martin and Brad Kahl discuss autologous stem cell transplantation for mantle cell lymphoma, the TRIANGLE trial results, and the transition toward use of Bruton tyrosine kinase inhibitors.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 31, 2023 Category: Consumer Health News Tags: Hematology-Oncology InDiscussion Source Type: news

Reversible BTK Inhibitor Gets FDA Nod for Mantle Cell Lymphoma
(MedPage Today) -- The FDA has granted accelerated approval to pirtobrutinib (Jaypirca), a non-covalent or reversible Bruton's tyrosine kinase (BTK) inhibitor, for the treatment of relapsed or refractory mantle cell lymphoma (MCL) after at least... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - January 30, 2023 Category: American Health Source Type: news

FDA Approves Pirtobrutinib for R/R Mantle Cell Lymphoma FDA Approves Pirtobrutinib for R/R Mantle Cell Lymphoma
This drug is the first BTK inhibitor approved to treat mantle cell lymphoma in this setting. Approval was based on overall response rates and duration of response in the phase 1/2 BRUIN trial.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 27, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Jaypirca (pirtobrutinib) for Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma
Jaypirca is the first BTK inhibitor of any kind specifically approved for patients with mantle cell lymphoma previously treated with a covalent BTK inhibitor In the BRUIN Phase 1/2 trial, covalent BTK inhibitor pre-treated patients with relapsed... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 27, 2023 Category: Drugs & Pharmacology Source Type: news

ODAC to Review Lymphoma Drug; Tobacco Control; Artificial Skin Aids Cancer Studies
(MedPage Today) -- The FDA announced that the Oncologic Drugs Advisory Committee (ODAC) will meet March 9 to review the accelerated approval of polatuzumab vedotin (Polivy) plus rituximab (Rituxan) and chemotherapy for untreated diffuse large B... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - January 27, 2023 Category: Hematology Source Type: news

MDM2 Inhibitor Breaks Through in Trial of Liposarcoma, Other Advanced Malignancies
(MedPage Today) -- Almost half of patients with advanced solid tumors or lymphomas experienced disease control with a drug that reactivates the TP53 tumor suppressor, a first-in-human study showed. Overall, the oral murine double minute-2 (MDM2... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - January 26, 2023 Category: Hematology Source Type: news

Analyzing Disparities in the Treatment of Mantle Cell Lymphoma Analyzing Disparities in the Treatment of Mantle Cell Lymphoma
Yazeed Sawalha, MD, discusses a study that analyzed how health disparities affect the likelihood of undergoing consolidated autologous stem cell transplant for mantle cell lymphoma.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 26, 2023 Category: Consumer Health News Tags: Hematology-Oncology MDAngle Source Type: news

FDA Approves New Drug for Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
MONDAY, Jan. 23, 2023 -- The U.S. Food and Drug Administration has approved zanubrutinib (Brukinsa), a next-generation BTK inhibitor, for the treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. The approval was... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 23, 2023 Category: General Medicine Source Type: news